TY - JOUR
T1 - The emergence of new biologics for severe asthma
AU - Eger, Katrien A. B.
AU - Bel, Elisabeth H.
N1 - Copyright © 2019. Published by Elsevier Ltd.
PY - 2019/6
Y1 - 2019/6
N2 - Patients with severe asthma experience severe symptoms and frequent exacerbations despite intensive treatment with inhaled and oral glucocorticoids. Biologics for severe asthma aim to reduce asthma-related and glucocorticoid-induced morbidity. Recently, new biologics targeting interleukin (IL)-5, IL-5 receptor and IL-4/IL-13, which are all cytokines involved in so-called type 2 airway inflammation, were approved for severe asthma. They show a reduction in exacerbation rate and an oral glucocorticoid-sparing effect. Studies with upstream biologics targeting alarmin cytokines such as thymic stromal lymphopoietin (TSLP) and IL-33 are underway, and newly designed bispecific antibodies targeting more than one pathway are in early phases of development. Such pathway-targeted add-on treatments will soon become standard of care for all patients with severe asthma.
AB - Patients with severe asthma experience severe symptoms and frequent exacerbations despite intensive treatment with inhaled and oral glucocorticoids. Biologics for severe asthma aim to reduce asthma-related and glucocorticoid-induced morbidity. Recently, new biologics targeting interleukin (IL)-5, IL-5 receptor and IL-4/IL-13, which are all cytokines involved in so-called type 2 airway inflammation, were approved for severe asthma. They show a reduction in exacerbation rate and an oral glucocorticoid-sparing effect. Studies with upstream biologics targeting alarmin cytokines such as thymic stromal lymphopoietin (TSLP) and IL-33 are underway, and newly designed bispecific antibodies targeting more than one pathway are in early phases of development. Such pathway-targeted add-on treatments will soon become standard of care for all patients with severe asthma.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067412740&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31229937
U2 - https://doi.org/10.1016/j.coph.2019.05.005
DO - https://doi.org/10.1016/j.coph.2019.05.005
M3 - Review article
C2 - 31229937
SN - 1471-4892
VL - 46
SP - 108
EP - 115
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
ER -